Is BIAF or BLLN more undervalued in 2026?

CirclFi compares bioAffinity Technologies, Inc. (BIAF) and BillionToOne, Inc. (BLLN) using 13 institutional-grade valuation models. BIAF has a Quality of Company score of 4.7/10 while BLLN scores 7.9/10.

Which is a better buy — BIAF or BLLN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BIAF and BLLN valuations compare?

BIAF at $1.65 and BLLN at $97.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BIAF vs BLLN Valuation Comparison 2026 — Intrinsic Value Analysis

BIAF

Diagnostics & Research

bioAffinity Technologies, Inc.

Quality

4.7

out of 10

Value Trap

WARN

Price

$1.65

Last close

Models

10/13

Active

BLLN

Diagnostics & Research

BillionToOne, Inc.

Quality

7.9

out of 10

Value Trap

—

Price

$97.80

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	BIAF Fair Value	BIAF Upside	BLLN Fair Value	BLLN Upside
Bayesian DCF	Intrinsic	$0.71	-56.7%	$4.12	-95.8%
Earnings Power Value	Intrinsic	—	—	$2.92	-97.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.18	-91.8%	$10.83	-88.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BIAF vs BLLN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BIAF vs BLLN — Which Stock Is More Undervalued?

BLLN scores higher with a 7.9/10 quality rating vs BIAF's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing bioAffinity Technologies, Inc. (BIAF) and BillionToOne, Inc. (BLLN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BIAF currently trades at $1.65 with a QOC of 4.7/10, while BLLN trades at $97.80 with a QOC of 7.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).